Novel Health Strategies to Present on Global Healthcare Reforms at International Society for Pharmacoeconomics and Outcomes (ISPOR) Latin America Meeting in Mexico
Novel Health Strategies, LLC, a leading life sciences strategy consulting firm has been selected to present a research study at the International Society for Pharmacoeconomics and Outcomes (ISPOR) Latin America Meeting in Mexico, to be held 8-10 September 2011.
IMPACT OF GLOBAL HEALTHCARE REFORMS ON PRICING, ACCESS AND HEALTH ECONOMICS AND OUTCOMES STRATEGY
During 2009-2011 major healthcare reforms were proposed and implemented in a number of nations, for example, Affordable Care Act in the United States, Arzneimittelmarktneuordnungsgesetz (AMNOG) in Germany, HSPT in France, KVG in Switzerland and NHS proposed reform in the UK. These reforms have significant implications on pricing, market access and health economics and outcomes research (HEOR) strategy for drug and device products. To understand the implications of these trends, Novel Health team analyzed 2009-2011 reform bills, proposed changes worldwide, and recent pricing and access trends.
Additionally, Novel Health interviewed public and private payers, key opinion leaders and payer-influencers to understand implications of these reforms on drug and device manufacturers.
Key highlights of this research were:
- The global healthcare landscape is expected to undergo significant change during 2012-2016.
- In the US, government will play increased role as a single payer, especially with―Medicare, Medicaid and CHIP programs― which will cover 114 million Americans, at a cost of $784 billion. The price discounts implemented for Medicare Part D, Part B and 340B clinics are likely to lead to downward pressure on pricing for pharmaceutical products.
- In Germany, AMNOG bill marked the end of free drug pricing and would lead to increased insurance premiums (now 15.5% of wages). There is an increased emphasis on demonstrating “additional benefit” versus comparators, which will be determined by G-BA.
- In the UK, NHS has proposed to replace PCTs with 500-1000 GP-led consortia and use value-based pricing for expensive drugs and devices.
- Overall, payers view that in the future, health technology assessments, including cost effectiveness analysis and comparative effectiveness research would play critical role in pricing, coverage and reimbursement of branded products.
Lead researcher of this study, Saurabh Aggarwal, PhD, Principal, Novel Health Strategies, said “During last 2-3 years, global landscape for healthcare products has changed significantly. To gain and maintain access for existing and new medical products it will be critical to demonstrate cost and comparative effectiveness versus standard of care”.
Full results of the research study are available upon request.
About Novel Health Strategies
Novel Health Strategies, LLC (“Novel Health”) is a team of experienced professionals who have expertise in healthcare strategy, research, policy, publications, health economics and outcomes research, modeling, and pricing and market access strategy. Novel Health team has led strategy projects for majority of Top 50 pharmaceutical, biotech and device companies. Novel Health has large network of internal and external stakeholders and has published several thought leading strategy perspectives, including the ‘What’s fueling the biotech engine’ series in Nature Biotech, which has been cited and quoted by more than a hundred peer-reviewed publications and agencies (FDA, EMA and others). Novel Health has presented several industry trends and perspectives at ISPOR, AMCP and BIO meetings. At a recent AMCP annual meeting, Novel Heath team’s study on trends in cost effectiveness was featured as one of the top highlights of the meeting.
- Contact Information
- Saurabh Aggarwal
- Novel Health Strategies
- Contact via E-mail
This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.